
Microorganisms, Journal Year: 2025, Volume and Issue: 13(5), P. 1077 - 1077
Published: May 6, 2025
The SARS-CoV-2 virus poses a significant risk to immunocompromised patients, who display weakened immunity and reduced seroconversion following infection vaccination. In this study, we recruited 19 hospitalized patients with immune disorders (ImCo) 4 immunocompetent controls (ICC) COVID-19. We evaluated their serological, humoral, cellular responses at <30 days >90 post-symptom onset. ICC showed robust B T cell against SARS-CoV-2, indicated by detectable antibody levels, memory antibody-secreting cells (mASCs) towards the spike protein spike-specific CD4+ CD8+ cells. ImCo impaired responses, lower levels of responses. Further subdivision demonstrates that solid organ transplant (SOT) generated similar whereas other including hematological malignancies anti-CD20 therapy, did not. Absolute numbers were low in but increased later time points. Our findings suggest even when reduced, could present response, suggesting more successful line passive immunization for individuals focusing on boosting
Language: Английский